Citation APA
Mathieu, C., Wych, J., Hendriks, E. A., Van Ryckeghem, L., Tree, T., Chmura, P., Möller, C., Casteels, K., Danne, T., Reschke, F., Šmigoc Schweiger, D., Battelino, T., Johannesen, J., Rami-Merhar, B., Pieber, T., De Block, C., Evans, M., Hilbrands, R., Bosi, E., Willemsen, R. H., Basu, S., Pulkkinen, M. A., Knip, M., Cnop, M., Nitsche, A., Schulte, A. M., Niemöller, E., Peakman, M., Wilhelm-Benartzi, C., Gillespie, D., Overbergh, L., Mander, A. P., Marcovecchio, M. L., & INNODIA, (2025). Minimum effective low dose of antithymocyte globulin in people aged 5-25 years with recent-onset stage 3 type 1 diabetes (MELD-ATG): a phase 2, multicentre, double-blind, randomised, placebo-controlled, adaptive dose-ranging trial. Lancet, 406(10510), 1375-1388. doi:10.1016/S0140-6736(25)01674-5
Permalink
http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/408956